Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2005 2
2010 3
2011 1
2014 1
2015 2
2017 1
2021 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

9 results

Results by year

Filters applied: . Clear all
Page 1
Treatment of patients with acute promyelocytic leukemia: a consensus statement on risk-adapted approaches to therapy.
Tallman M, Douer D, Gore S, Powell BL, Ravandi F, Rowe J, Ranganathan A, Sanz MA. Tallman M, et al. Clin Lymphoma Myeloma Leuk. 2010 Oct;10 Suppl 3:S122-6. doi: 10.3816/CLML.2010.s.023. Clin Lymphoma Myeloma Leuk. 2010. PMID: 21115429
Cure in APL is also largely dependent on timely and effective supportive care measures that counteract such life-threatening emergencies as coagulopathy and APL differentiation syndrome. The risk of mortality during induction and the risk of relapse following …
Cure in APL is also largely dependent on timely and effective supportive care measures that counteract such life-threatening emergencies as …
Characteristics and predictors of early hospital deaths in newly diagnosed APL: a 13-year population-wide study.
Gill H, Yung Y, Chu HT, Au WY, Yip PK, Lee E, Yim R, Lee P, Cheuk D, Ha SY, Leung RYY, Ma ESK, Kumana CR, Kwong YL. Gill H, et al. Blood Adv. 2021 Jul 27;5(14):2829-2838. doi: 10.1182/bloodadvances.2021004789. Blood Adv. 2021. PMID: 34269798 Free PMC article.
ED occurred in 56 patients (16%): 11 (3%) died in the first 2 days after admission (intracranial hemorrhage [ICH], n = 6; APL-differentiation syndrome [APL-DS], n = 4; infection, n = 1); 22 (6%) died within 3 to 7 days (ICH, n = 12; APL-DS, n = 8; infections, …
ED occurred in 56 patients (16%): 11 (3%) died in the first 2 days after admission (intracranial hemorrhage [ICH], n = 6; APL-diff …
The expression of p38, ERK1 and Bax proteins has increased during the treatment of newly diagnosed acute promyelocytic leukemia with arsenic trioxide.
Mandegary A, Hosseini R, Ghaffari SH, Alimoghaddam K, Rostami S, Ghavamzadeh A, Ghahremani MH. Mandegary A, et al. Ann Oncol. 2010 Sep;21(9):1884-1890. doi: 10.1093/annonc/mdq034. Epub 2010 Feb 17. Ann Oncol. 2010. PMID: 20164150 Free article.
Clinical findings and white blood cell counts were recorded as well. RESULTS: Complete remission was observed in 17 (85%) patients with the median duration of 28 days (18-38) and cumulative dosage of median 280 mg (180-350). Hyperleukocytosis and APL differentiat …
Clinical findings and white blood cell counts were recorded as well. RESULTS: Complete remission was observed in 17 (85%) patients wi …
Acute promyelocytic leukemia in patients aged >70 years: the cure beyond the age.
Finsinger P, Breccia M, Minotti C, Carmosino I, Girmenia C, Chisini M, Volpicelli P, Vozella F, Romano A, Montagna C, Colafigli G, Cimino G, Avvisati G, Petti MC, Lo-Coco F, Foà R, Latagliata R. Finsinger P, et al. Ann Hematol. 2015 Feb;94(2):195-200. doi: 10.1007/s00277-014-2197-7. Epub 2014 Sep 4. Ann Hematol. 2015. PMID: 25186786
To address this issue, we reviewed treatment results in 13 patients aged >70 years with newly diagnosed APL followed at our institution from January 1991 to December 2008. According to Sanz score, seven patients were at low risk, five at intermediate risk, and one at hi …
To address this issue, we reviewed treatment results in 13 patients aged >70 years with newly diagnosed APL followed at our institution f …
Phase II study of single-agent arsenic trioxide for the front-line therapy of acute promyelocytic leukemia.
Ghavamzadeh A, Alimoghaddam K, Rostami S, Ghaffari SH, Jahani M, Iravani M, Mousavi SA, Bahar B, Jalili M. Ghavamzadeh A, et al. J Clin Oncol. 2011 Jul 10;29(20):2753-7. doi: 10.1200/JCO.2010.32.2107. Epub 2011 Jun 6. J Clin Oncol. 2011. PMID: 21646615 Clinical Trial.
After achieving CR, the patients received one to four more courses of therapy with arsenic trioxide as consolidation and were observed with reverse-transcriptase polymerase chain reaction studies from peripheral blood (to detect of minimal residual disease) every 3 months …
After achieving CR, the patients received one to four more courses of therapy with arsenic trioxide as consolidation and were observed …
Induction of CXC and CC chemokines by all-trans retinoic acid in acute promyelocytic leukemia cells.
Shibakura M, Niiya K, Niiya M, Asaumi N, Yoshida C, Nakata Y, Tanimoto M. Shibakura M, et al. Leuk Res. 2005 Jul;29(7):755-9. doi: 10.1016/j.leukres.2005.01.005. Epub 2005 Feb 26. Leuk Res. 2005. PMID: 15927671
We previously reported the induction of interleukin-8 (IL-8), one of the CXC chemokines, by all-trans retinoic acid (ATRA) in PL-21 and NB4 human myeloid leukemia cells, which may be implicated in APL differentiation syndrome that is a relatively frequent com …
We previously reported the induction of interleukin-8 (IL-8), one of the CXC chemokines, by all-trans retinoic acid (ATRA) in PL-21 and NB4 …
Induction, consolidation, and maintenance therapies with arsenic as a single agent for acute promyelocytic leukaemia in a 11-year follow-up.
Aznab M, Rezaei M. Aznab M, et al. Hematol Oncol. 2017 Mar;35(1):113-117. doi: 10.1002/hon.2253. Epub 2015 Aug 27. Hematol Oncol. 2017. PMID: 26310595
The rates of complete remission, disease-free survival, overall survival, and drug toxicity were evaluated. The morphologic complete remission was observed in 55 out of the 60 patients. The most common causes of a remission failure were early mortality because of the AP …
The rates of complete remission, disease-free survival, overall survival, and drug toxicity were evaluated. The morphologic complete remissi …
Does microgranular variant morphology of acute promyelocytic leukemia independently predict a less favorable outcome compared with classical M3 APL? A joint study of the North American Intergroup and the PETHEMA Group.
Tallman MS, Kim HT, Montesinos P, Appelbaum FR, de la Serna J, Bennett JM, Deben G, Bloomfield CD, Gonzalez J, Feusner JH, Gonzalez M, Gallagher R, Miguel JD, Larson RA, Milone G, Paietta E, Rayon C, Rowe JM, Rivas C, Schiffer CA, Vellenga E, Shepherd L, Slack JL, Wiernik PH, Willman CL, Sanz MA. Tallman MS, et al. Blood. 2010 Dec 16;116(25):5650-9. doi: 10.1182/blood-2010-06-288613. Epub 2010 Sep 21. Blood. 2010. PMID: 20858857 Free PMC article. Clinical Trial.
The complete remission rate for all 155 patients was 82%, compared with 89% for 748 patients with classical M3 disease. The incidence of the APL differentiation syndrome was 26%, compared with 25% for classical M3 patients, and the early death rate was 13.6% …
The complete remission rate for all 155 patients was 82%, compared with 89% for 748 patients with classical M3 disease. The incidence of the …
Arsenic trioxide therapy in relapsed or refractory Japanese patients with acute promyelocytic leukemia: updated outcomes of the phase II study and postremission therapies.
Shigeno K, Naito K, Sahara N, Kobayashi M, Nakamura S, Fujisawa S, Shinjo K, Takeshita A, Ohno R, Ohnishi K. Shigeno K, et al. Int J Hematol. 2005 Oct;82(3):224-9. doi: 10.1532/IJH97.05044. Int J Hematol. 2005. PMID: 16207595 Clinical Trial.
At a median follow-up of 30 months, the estimated 2-year overall survival rate was 56%, and the estimated 2-year event-free survival rate was 17%. During the ATO therapy, QTc prolongation was observed in most cases. Fifteen patients developed ventricular tachycardia, and 1 …
At a median follow-up of 30 months, the estimated 2-year overall survival rate was 56%, and the estimated 2-year event-free survival rate wa …